{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T01:15:25Z","timestamp":1788830125274,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background\/objectives<\/jats:title>\n                    <jats:p>Adalimumab (ADA) is a well-established treatment for refractory paediatric uveitis; however, some patients remain inadequately controlled on standard biweekly dosing. Weekly ADA injections are increasingly used, though evidence in paediatric cohorts remains limited. This study evaluates outcomes of escalation to weekly ADA in children with refractory uveitis and explores the relevance of serum drug levels and anti-ADA antibodies (AAA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Subjects\/methods<\/jats:title>\n                    <jats:p>Patients with idiopathic uveitis at two tertiary centres in the UK treated with weekly adalimumab were retrospectively reviewed. Demographic, clinical and laboratory data were collected, including age at escalation, systemic diagnosis, serum ADA levels, AAA titres pre- and post-escalation, clinical response and complications. Treatment success was defined as \u22640.5+ anterior chamber cells and &lt;2 drops\/day of steroid eye drops at 3 months, or most recent follow-up where escalation occurred within 3 months of review.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>15 patients were included. Mean age at escalation was 11 years (range: 3-17). 11 (73%) had a systemic diagnosis; most commonly juvenile idiopathic arthritis (60%). Median serum level pre-escalation was 10.1\u2009mg\/L (IQR: 7.8\u201311.9) and 18.1\u2009mg\/L (IQR: 14.8\u201322.1) post escalation. AAAs were detectable in 7\/15 (47%) pre-escalation, 2\/15 (13.3%) post-escalation. Success occurred in 10\/15 (67%), with visual acuity stable and improved in 93%. No serious systemic adverse events were reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Weekly ADA offers a safe and effective treatment alternative for children with refractory uveitis, including those with AAAs. These findings support its inclusion in future treatment pathways, though the predictive value of serum levels and AAAs remains uncertain and warrants further investigation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s41433-026-04460-x","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T17:16:54Z","timestamp":1780075014000},"page":"1669-1675","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical outcomes of weekly adalimumab in refractory non-infectious paediatric uveitis and the role of serum drug levels and anti-adalimumab antibodies"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-1877-971X","authenticated-orcid":false,"given":"Amelia","family":"Rees","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raheej","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1874-1953","authenticated-orcid":false,"given":"Jessy","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare","family":"Nash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Hawley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasa","family":"Pockar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiao Wei","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilia","family":"Varnier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Chieng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Ashworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"4460_CR1","doi-asserted-by":"publisher","first-page":"e301","DOI":"10.1097\/RHU.0000000000001707","volume":"28","author":"JE Roberts","year":"2022","unstructured":"Roberts JE, Nigrovic PA, Lo MS, Chang MH. Weekly Adalimumab, an Effective Alternative for Refractory Uveitis in Children. J Clin Rheumatol. 2022;28:e301\u2013e4.","journal-title":"J Clin Rheumatol"},{"key":"4460_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2019.108322","volume":"211","author":"ES Sen","year":"2020","unstructured":"Sen ES, Ramanan AV. Juvenile idiopathic arthritis-associated uveitis. Clin Immunol. 2020;211:108322.","journal-title":"Clin Immunol"},{"key":"4460_CR3","doi-asserted-by":"publisher","first-page":"e994","DOI":"10.1111\/aos.15012","volume":"100","author":"CV Kouwenberg","year":"2022","unstructured":"Kouwenberg CV, Koopman-Kalinina Ayuso V, de Boer JH. Clinical benefits and potential risks of adalimumab in non-JIA chronic paediatric uveitis. Acta Ophthalmol. 2022;100:e994\u2013e1001.","journal-title":"Acta Ophthalmol"},{"key":"4460_CR4","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13075-025-03531-w","volume":"27","author":"K Baquet-Walscheid","year":"2025","unstructured":"Baquet-Walscheid K, Minden K, Niewerth M, Dressler F, Foeldvari I, Foell D, et al. Course of uveitis in children with juvenile idiopathic arthritis (JIA): Five years follow-up data from a prospective multicenter Inception Cohort of Newly diagnosed patients with JIA (ICON-JIA) study. Arthritis Res Ther. 2025;27:61.","journal-title":"Arthritis Res Ther"},{"key":"4460_CR5","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1056\/NEJMoa1614160","volume":"376","author":"AV Ramanan","year":"2017","unstructured":"Ramanan AV, Dick AD, Jones AP, McKay A, Williamson PR, Compeyrot-Lacassagne S, et al. Adalimumab plus Methotrexate for Uveitis in Juvenile Idiopathic Arthritis. N Engl J Med. 2017;376:1637\u201346.","journal-title":"N Engl J Med"},{"key":"4460_CR6","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1007\/s10792-024-03289-1","volume":"44","author":"RE Ruiz-Lozano","year":"2024","unstructured":"Ruiz-Lozano RE, Mousa HM, Soifer M, Azar NS, Quiroga-Garza ME, Dzhaber D, et al. Adalimumab to treat noninfectious pediatric chronic anterior uveitis: a case series. Int Ophthalmol. 2024;44:376.","journal-title":"Int Ophthalmol"},{"key":"4460_CR7","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1097\/BOR.0000000000000316","volume":"28","author":"ST Angeles-Han","year":"2016","unstructured":"Angeles-Han ST, Rabinovich CE. Uveitis in children. Curr Opin Rheumatol. 2016;28:544\u20139.","journal-title":"Curr Opin Rheumatol"},{"key":"4460_CR8","volume":"16","author":"RA Ghanma","year":"2024","unstructured":"Ghanma RA, Steeples L, Pockar S, Sharma V, Chieng A, Ashworth J. Adalimumab (ADA) in Pediatric non-infectious uveitis: an observational study. Cureus. 2024;16:e59019.","journal-title":"Cureus"},{"key":"4460_CR9","doi-asserted-by":"publisher","first-page":"337","DOI":"10.4274\/tjo.galenos.2024.70371","volume":"54","author":"K Ozdemir Yalcinsoy","year":"2024","unstructured":"Ozdemir Yalcinsoy K, Ozen O, Ozdamar Erol Y, Cakar Ozda P. The efficacy of adalimumab treatment in pediatric non-infectious uveitis: a retrospective cohort study. Turk J Ophthalmol. 2024;54:337\u201343.","journal-title":"Turk J Ophthalmol"},{"key":"4460_CR10","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1080\/09273948.2023.2279682","volume":"31","author":"J Huard","year":"2023","unstructured":"Huard J, Mihailescu SD, Muraine M, Raymond S, Grall Lerosey M, Gueudry J. Effectiveness and safety of weekly adalimumab for non-infectious chronic anterior uveitis in children. Ocul Immunol Inflamm. 2023;31:2039\u201349.","journal-title":"Ocul Immunol Inflamm"},{"key":"4460_CR11","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1080\/1744666X.2017.1288097","volume":"13","author":"KC LaMattina","year":"2017","unstructured":"LaMattina KC, Goldstein DA. Adalimumab for the treatment of uveitis. Expert Rev Clin Immunol. 2017;13:181\u20138.","journal-title":"Expert Rev Clin Immunol"},{"key":"4460_CR12","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1080\/25785826.2019.1642080","volume":"42","author":"E Hasegawa","year":"2019","unstructured":"Hasegawa E, Takeda A, Yawata N, Sonoda KH. The effectiveness of adalimumab treatment for non-infectious uveitis. Immunol Med. 2019;42:79\u201383.","journal-title":"Immunol Med"},{"key":"4460_CR13","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1016\/j.ophtha.2020.04.009","volume":"127","author":"J Lee","year":"2020","unstructured":"Lee J, Koreishi AF, Zumpf KB, Minkus CL, Goldstein DA. Success of weekly adalimumab in refractory ocular inflammatory disease. Ophthalmology. 2020;127:1431\u20133.","journal-title":"Ophthalmology"},{"key":"4460_CR14","unstructured":"NHS England. Infliximab (Remicade) as Anti-TNF Alpha Treatment Option for Paediatric Patients with Severe Refractory Uveitis. London: NHS England; 2015. Report No.: D12\/P\/b."},{"key":"4460_CR15","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1136\/annrheumdis-2017-212089","volume":"77","author":"P Quartier","year":"2018","unstructured":"Quartier P, Baptiste A, Despert V, Allain-Launay E, Kone-Paut I, Belot A, et al. ADJUVITE: a double-blind, randomised, placebo-controlled trial of adalimumab in early onset, chronic, juvenile idiopathic arthritis-associated anterior uveitis. Ann Rheum Dis. 2018;77:1003\u201311.","journal-title":"Ann Rheum Dis"},{"key":"4460_CR16","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s10067-017-3890-4","volume":"37","author":"CK Correll","year":"2018","unstructured":"Correll CK, Bullock DR, Cafferty RM, Vehe RK. Safety of weekly adalimumab in the treatment of juvenile idiopathic arthritis and pediatric chronic uveitis. Clin Rheumatol. 2018;37:549\u201353.","journal-title":"Clin Rheumatol"},{"key":"4460_CR17","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.jaapos.2013.06.009","volume":"17","author":"L Bravo-Ljubetic","year":"2013","unstructured":"Bravo-Ljubetic L, Peralta-Calvo J, Noval S, Pastora-Salvador N, Abelairas-Gomez J, Merino R. Adalimumab therapy for refractory childhood uveitis. J AAPOS. 2013;17:456\u20139.","journal-title":"J AAPOS"},{"key":"4460_CR18","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/S0140-6736(16)31339-3","volume":"388","author":"QD Nguyen","year":"2016","unstructured":"Nguyen QD, Merrill PT, Jaffe GJ, Dick AD, Kurup SK, Sheppard J, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet. 2016;388:1183\u201392.","journal-title":"Lancet"},{"key":"4460_CR19","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1097\/MIB.0000000000000715","volume":"22","author":"MC Dubinsky","year":"2016","unstructured":"Dubinsky MC, Rosh J, Faubion WA Jr., Kierkus J, Ruemmele F, Hyams JS, et al. Efficacy and Safety of Escalation of Adalimumab Therapy to Weekly Dosing in Pediatric Patients with Crohn\u2019s Disease. Inflamm Bowel Dis. 2016;22:886\u201393.","journal-title":"Inflamm Bowel Dis"},{"key":"4460_CR20","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1111\/apt.12863","volume":"40","author":"D Wolf","year":"2014","unstructured":"Wolf D, D\u2019Haens G, Sandborn WJ, Colombel JF, Van Assche G, Robinson AM, et al. Escalation to weekly dosing recaptures response in adalimumab-treated patients with moderately to severely active ulcerative colitis. Aliment Pharmacol Ther. 2014;40:486\u201397.","journal-title":"Aliment Pharmacol Ther"},{"key":"4460_CR21","doi-asserted-by":"publisher","first-page":"e26190","DOI":"10.1097\/MD.0000000000026190","volume":"100","author":"JW Lu","year":"2021","unstructured":"Lu JW, Huang YW, Chen TL. Efficacy and safety of adalimumab in hidradenitis suppurativa: A systematic review and meta-analysis of randomized controlled trials. Medicine. 2021;100:e26190.","journal-title":"Medicine"},{"key":"4460_CR22","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s40257-017-0341-6","volume":"19","author":"C Ryan","year":"2018","unstructured":"Ryan C, Sobell JM, Leonardi CL, Lynde CW, Karunaratne M, Valdecantos WC, et al. Safety of Adalimumab Dosed Every Week and Every Other Week: Focus on Patients with Hidradenitis Suppurativa or Psoriasis. Am J Clin Dermatol. 2018;19:437\u201347.","journal-title":"Am J Clin Dermatol"},{"key":"4460_CR23","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1111\/jdv.16023","volume":"34","author":"HH van der Zee","year":"2020","unstructured":"van der Zee HH, Longcore M, Geng Z, Garg A. Weekly adalimumab treatment decreased disease flare in hidradenitis suppurativa over 36 weeks: integrated results from the phase 3 PIONEER trials. J Eur Acad Dermatol Venereol. 2020;34:1050\u20136.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"4460_CR24","doi-asserted-by":"publisher","first-page":"1564","DOI":"10.1080\/09273948.2020.1749857","volume":"29","author":"P Liberman","year":"2021","unstructured":"Liberman P, Berkenstock MK, Burkholder BM, Chaon BC, Thorne JE. Escalation to Weekly Adalimumab for the Treatment of Ocular Inflammation. Ocul Immunol Inflamm. 2021;29:1564\u20138.","journal-title":"Ocul Immunol Inflamm"},{"key":"4460_CR25","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3109\/03009742.2010.517546","volume":"40","author":"M Trachana","year":"2011","unstructured":"Trachana M, Pratsidou-Gertsi P, Pardalos G, Kozeis N, Badouraki M, Kanakoudi-Tsakalidou F. Safety and efficacy of adalimumab treatment in Greek children with juvenile idiopathic arthritis. Scand J Rheumatol. 2011;40:101\u20137.","journal-title":"Scand J Rheumatol"},{"key":"4460_CR26","unstructured":"Foundation PS Python (Version 3.11). https:\/\/www.python.org\/: Python Software Foundation; 2023."},{"key":"4460_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.xops.2023.100352","volume":"4","author":"A Brant","year":"2024","unstructured":"Brant A, Kolomeyer N, Goldberg JL, Haller J, Lee CS, Lee AY, et al. Evaluating Visual Acuity in the American Academy of Ophthalmology IRIS(R) Registry. Ophthalmol Sci. 2024;4:100352.","journal-title":"Ophthalmol Sci"},{"key":"4460_CR28","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1111\/j.1365-2133.2012.11041.x","volume":"167","author":"C Leonardi","year":"2012","unstructured":"Leonardi C, Sobell JM, Crowley JJ, Mrowietz U, Bao Y, Mulani PM, et al. Efficacy, safety and medication cost implications of adalimumab 40 mg weekly dosing in patients with psoriasis with suboptimal response to 40 mg every other week dosing: results from an open-label study. Br J Dermatol. 2012;167:658\u201367.","journal-title":"Br J Dermatol"},{"key":"4460_CR29","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.3899\/jrheum.120964","volume":"40","author":"EC Keystone","year":"2013","unstructured":"Keystone EC, van der Heijde D, Kavanaugh A, Kupper H, Liu S, Guerette B, et al. Clinical, functional, and radiographic benefits of longterm adalimumab plus methotrexate: final 10-year data in longstanding rheumatoid arthritis. J Rheumatol. 2013;40:1487\u201397.","journal-title":"J Rheumatol"},{"key":"4460_CR30","doi-asserted-by":"publisher","first-page":"151.e1","DOI":"10.1016\/j.jaapos.2019.02.006","volume":"23","author":"N Ashkenazy","year":"2019","unstructured":"Ashkenazy N, Saboo US, Abraham A, Ronconi C, Cao JH. Successful treatment with infliximab after adalimumab failure in pediatric noninfectious uveitis. J AAPOS. 2019;23:151.e1\u2013e5.","journal-title":"J AAPOS"},{"key":"4460_CR31","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1136\/ejhpharm-2018-001833","volume":"27","author":"C Trigo-Vicente","year":"2020","unstructured":"Trigo-Vicente C, Gimeno-Ballester V, Lopez-Del Val A. Cost-effectiveness analysis of infliximab, adalimumab, golimumab, vedolizumab and tofacitinib for moderate to severe ulcerative colitis in Spain. Eur J Hosp Pharm. 2020;27:355\u201360.","journal-title":"Eur J Hosp Pharm"},{"key":"4460_CR32","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.crohns.2013.09.017","volume":"8","author":"GK Choi","year":"2014","unstructured":"Choi GK, Collins SD, Greer DP, Warren L, Dowson G, Clark T, et al. Costs of adalimumab versus infliximab as first-line biological therapy for luminal Crohn\u2019s disease. J Crohns Colitis. 2014;8:375\u201383.","journal-title":"J Crohns Colitis"},{"key":"4460_CR33","doi-asserted-by":"publisher","first-page":"123","DOI":"10.2174\/1874312901711010123","volume":"11","author":"C Thorne","year":"2017","unstructured":"Thorne C, Boire G, Chow A, Garces K, Liu F, Poulin-Costello M, et al. Dose Escalation and Co-therapy Intensification Between Etanercept, Adalimumab, and Infliximab: The CADURA Study. Open Rheumatol J. 2017;11:123\u201335.","journal-title":"Open Rheumatol J"},{"key":"4460_CR34","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1016\/j.ophtha.2016.08.025","volume":"123","author":"M Cordero-Coma","year":"2016","unstructured":"Cordero-Coma M, Calleja-Antolin S, Garzo-Garcia I, Nunez-Garnes AM, Alvarez-Castro C, Franco-Benito M, et al. Adalimumab for Treatment of Noninfectious Uveitis: Immunogenicity and Clinical Relevance of Measuring Serum Drug Levels and Antidrug Antibodies. Ophthalmology. 2016;123:2618\u201325.","journal-title":"Ophthalmology"},{"key":"4460_CR35","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1001\/jamaophthalmol.2022.5584","volume":"141","author":"S Bellur","year":"2023","unstructured":"Bellur S, McHarg M, Kongwattananon W, Vitale S, Sen HN, Kodati S. Antidrug Antibodies to Tumor Necrosis Factor alpha Inhibitors in Patients With Noninfectious Uveitis. JAMA Ophthalmol. 2023;141:150\u20136.","journal-title":"JAMA Ophthalmol"},{"key":"4460_CR36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ajo.2024.07.010","volume":"270","author":"TM Janetos","year":"2025","unstructured":"Janetos TM, Kanwar K, Bashey S, Koreishi A, Goldstein DA. Predictors of Therapy Success in Weekly Adalimumab for Refractory Uveitis: A Retrospective Cohort Study. Am J Ophthalmol. 2025;270:1\u20137.","journal-title":"Am J Ophthalmol"},{"key":"4460_CR37","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.ajo.2024.09.008","volume":"268","author":"F Pichi","year":"2024","unstructured":"Pichi F, Smith SD, AlAli SH, Neri P. Adalimumab Drug Monitoring and Treatment Adjustment to Drug Antibodies in Noninfectious Uveitis. Am J Ophthalmol. 2024;268:306\u201311.","journal-title":"Am J Ophthalmol"},{"key":"4460_CR38","doi-asserted-by":"publisher","first-page":"2158","DOI":"10.4103\/ijo.IJO_1993_22","volume":"71","author":"P Sivakoti","year":"2023","unstructured":"Sivakoti P, Swaminathan M, Magesan K, Pyare R, George AE, Ganesh SK, et al. Visual outcome in pediatric uveitis: A retrospective data review in 277 children. Indian J Ophthalmol. 2023;71:2158\u201361.","journal-title":"Indian J Ophthalmol"},{"key":"4460_CR39","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.ophtha.2013.09.023","volume":"121","author":"MH Levin","year":"2014","unstructured":"Levin MH, Pistilli M, Daniel E, Gangaputra SS, Nussenblatt RB, Rosenbaum JT, et al. Incidence of visual improvement in uveitis cases with visual impairment caused by macular edema. Ophthalmology. 2014;121:588\u201395.e1.","journal-title":"Ophthalmology"},{"key":"4460_CR40","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1016\/j.ophtha.2020.01.036","volume":"127","author":"JE Thorne","year":"2020","unstructured":"Thorne JE, Woreta FA, Dunn JP, Jabs DA. Risk of Cataract Development among Children with Juvenile Idiopathic Arthritis-Related Uveitis Treated with Topical Corticosteroids. Ophthalmology. 2020;127:S21\u2013S6.","journal-title":"Ophthalmology"},{"key":"4460_CR41","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1016\/j.ophtha.2015.06.041","volume":"122","author":"S Kothari","year":"2015","unstructured":"Kothari S, Foster CS, Pistilli M, Liesegang TL, Daniel E, Sen HN, et al. The Risk of Intraocular Pressure Elevation in Pediatric Noninfectious Uveitis. Ophthalmology. 2015;122:1987\u20132001.","journal-title":"Ophthalmology"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04460-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04460-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04460-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:12:46Z","timestamp":1785517966000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04460-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":41,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["4460"],"URL":"https:\/\/doi.org\/10.1038\/s41433-026-04460-x","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"assertion":[{"value":"7 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}